Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2013-11-12 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document explicitly announces the "revenue for the third quarter of 2013" and provides detailed income statement tables comparing Q3 2013 results (9 months and the quarter itself) against prior periods. This content structure—focusing on period-specific financial performance highlights immediately following the announcement—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a full Interim/Quarterly Report (IR), as it focuses on key revenue figures and operational highlights rather than a full set of audited financial statements and extensive MD&A typical of those longer forms. Since it is the initial announcement of period results, ER is the most appropriate classification. Q3 2013
2013-11-12 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly financial update from Nanobiotix for the third quarter of 2013. It contains specific revenue figures, tables comparing current and prior period performance, and a management discussion of business activities and clinical progress. While it is an announcement of results, it provides substantive financial data and analysis rather than just a notification of a report's availability, fitting the definition of an Interim/Quarterly Report (IR). Q3 2013
2013-11-12 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated November 7, 2013, announcing that NANOBIOTIX was distinguished at the INVESTOR AWARDS 2013. It discusses the success of its 2012 IPO and its focus on clinical development. Crucially, it contains a forward-looking statement: "Prochaine communication financière : chiffre d'affaires du troisième trimestre 2013, le 14 novembre 2013" (Next financial communication: third-quarter 2013 revenue, on November 14, 2013). This structure—an announcement about an award/event followed by a notice about an upcoming financial report—is characteristic of a general regulatory announcement or press release that doesn't fit the specific definitions of an Earnings Release (ER) (which would contain the results) or an Interim Report (IR) (which would contain the full financials). Since it is a general corporate announcement that doesn't fit other specific categories like DIRS, DIV, or CAP, the most appropriate fallback is Regulatory Filings (RNS). The document length (4153 chars) is short enough that if it were announcing a report, it would be an RPA, but here it is announcing an award and a future earnings date, making RNS the best fit for a general corporate update.
2013-11-07 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of October 31, 2013. This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to major shareholding notifications or capital structure updates, but the core content is the monthly count of shares/votes. This aligns best with 'Major Shareholding Notification' (MRQ) as it reports on the capital structure basis used for threshold crossings, or potentially 'Regulatory Filings' (RNS) if a more specific category isn't available. Given the explicit focus on the total number of shares and voting rights, MRQ is the most precise fit among the provided options, as these reports are often triggered by or used in conjunction with major shareholding changes, even if this specific one is a routine monthly update on the total base.
2013-11-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of September 30, 2013. This structure is characteristic of a mandatory regulatory disclosure concerning the company's share capital and voting rights structure, which falls under general regulatory announcements or specific share/capital change notifications. Since it is a monthly update on the total number of shares and voting rights, it directly relates to the capital structure. However, the provided definitions do not have a specific code for 'Monthly Voting Rights Disclosure'. The closest fit among the options is 'SHA' (Share Issue/Capital Change) as it reports on the capital structure, or 'RNS' (Regulatory Filings) as a general catch-all for mandatory regulatory disclosures not covered elsewhere. Given the specific nature of reporting total voting rights, which is a key component of capital structure reporting, SHA is a strong candidate. However, since the primary focus is reporting the *count* of shares/votes rather than announcing a *change* (like an issue or split), and it is a recurring regulatory filing, RNS (Regulatory Filings) is often used for these periodic, non-event-driven capital structure disclosures when a more specific code isn't available. Looking closely at the definitions, 'SHA' is for 'Announcement regarding new share issues, stock splits, or other capital changes.' This document reports the *current state* of the capital, not an announcement of a change. Therefore, 'RNS' (Regulatory Filings) is the most appropriate fallback for this mandatory, periodic regulatory disclosure that doesn't fit the specific event-driven codes.
2013-10-03 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 30, 2013, announcing the launch of a dedicated mobile application for Nanobiotix shareholders and potential shareholders. The content focuses on providing real-time access to stock quotes, press releases, interviews, and financial documents via the app. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or an interim report (IR). It is an announcement about a new communication tool aimed at investors. Since it is a general announcement regarding company news and investor relations that doesn't fit the specific categories like DIV, DIRS, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, although 'Report Publication Announcement' (RPA) is sometimes used for announcements about investor tools, RNS is the broader fallback for non-standard corporate news releases.
2013-09-30 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.